PARIS (Reuters) – Sanofi said on Wednesday it would review available information and run consultations before deciding whether to enroll patients again for its COVID-19-related hydroxychloroquine trials.

The French drugmaker said on May 29 it had stopped recruiting new COVID-19 subjects for two clinical trials on hydroxychloroquine until concerns about safety are cleared up following a decision by the World Health Organization to pause a large trial.

The WHO said earlier in the day the trial would resume.

“We will review available information and run consultations in the coming days to reassess our position,” a spokesman with Sanofi said.